Trial Profile
Effect of Ferric Carboxymaltose on Exercise Capacity After Kidney Transplantation: a Multicenter Randomized Controlled Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Pharmacodynamics
- Acronyms EFFECT-KTx
- 23 Feb 2024 Planned End Date changed from 1 Dec 2023 to 1 Sep 2024.
- 23 Feb 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Sep 2024.
- 23 Feb 2024 Status changed from recruiting to active, no longer recruiting.